Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€222.50

€222.50

3.300%
7.1
3.300%
€259.74
 
15:23 / Tradegate WKN: 895878 / Symbol: RMD / Name: ResMed / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Resmed Inc. Stock

A very strong showing by Resmed Inc. today, with an increase of €7.10 (3.300%) compared to yesterday's price.
The stock is an absolute favorite of our community with 24 Buy predictions and no Sell predictions.
As a result the target price of 259 € shows a slightly positive potential of 16.4% compared to the current price of 222.5 € for Resmed Inc..

Pros and Cons of Resmed Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Resmed Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Resmed Inc. 3.300% -0.874% 4.411% -11.358% 3.309% 4.285% 28.982%
Thermo Fisher Scientific Inc. -1.090% -9.087% -0.463% -9.353% 0.111% -6.262% 17.784%
Veeva Systems A 0.370% -8.477% -8.213% -21.393% -8.381% 11.171% -22.947%
QuidelOrtho Corp. -0.880% -13.077% -9.600% -46.190% -9.600% -71.572% -89.135%

Comments

ResMed (NYSE:RMD) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Ratings data for RMD provided by MarketBeat
Show more

ResMed (NYSE:RMD) had its "overweight" rating reaffirmed by analysts at KeyCorp.
Ratings data for RMD provided by MarketBeat
Show more

ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for RMD provided by MarketBeat
Show more

News

Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.